文献速递流行病学与生物统计临床试验与 GCP

当代临床试验中的胜率法:应用增长与解读挑战的元流行病学研究

The win ratio in contemporary clinical trials: growing adoption and interpretation challenges-a meta-epidemiological study.
PubMed 文献 · J Clin Epidemiol · 2026-05-12

该元流行病学研究系统评价了胜率法(WR)在临床试验中的应用趋势与解读问题。共纳入90项研究(35项预设终点分析、55项再分析),循环系统试验约占80%。结论层面35项中22项与原始试验一致,差异多与终点成分选择或优先级变化有关。

要点

  • WR应用持续增长并扩展至心血管以外领域。
  • 成分方向与总体WR结果不一致并不少见。
  • WR再分析中终点成分变化可能影响临床解读。

核心结论

  • WR在临床研究中的应用稳步增长并扩展至心血管试验之外。
  • 基于WR构建的层次复合终点在成分选择上可能不同于传统复合终点,成分间方向不一致并不少见。
  • 在WR再分析中,终点成分的变化可能影响临床解读。

研究设计与样本

  • 采用PRISMA 2020系统检索PubMed、Embase和Web of Science(检索日期:2025年3月26日)。
  • 纳入以个体数据用WR总结治疗效应的已发表临床试验或再分析,共90项研究:35项预设终点分析和55项再分析。

主要发现

  • 循环系统试验约占WR应用的80%。
  • 35项结论层面比较研究中,22项WR报告的结论与原始试验一致。
  • 几乎所有观察到的结论差异均与终点成分的选择或优先级变化相关。

临床怎么用

  • 应用WR时需审慎关注分析框架的适当性、终点定义和结果解读,以确保WR报告分析的可解释性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The win ratio (WR) has been used with increasing frequency in clinical trials with hierarchical composite end points. This meta-epidemiological study aims to systematically evaluate the contemporary use of the WR in clinical trials. Specifically, we sought to (1) describe temporal trends in WR application, (2) quantify its use across therapeutic areas, and (3) examine component directional contributions and conclusion consistency between analyses summarized by the WR and the original analyses. METHODS: We conducted a systematic review (PRISMA 2020) of PubMed, Embase, and Web of Science (search date: 26 March 2025). Eligible studies were published clinical trials or reanalyses that summarized treatment effects using the WR based on individual data. Studies were classified by application type (prespecified vs reanalysis) and mapped to International Classification of Diseases (ICD-10) categories. After inclusion, we further screened for studies with comparable data, then performed two comparisons: first, the component directional contribution between end point component and the overall WR result; and second, the conclusion-level consistency between each WR-reported analyses and the conclusions of the original trials. RESULTS: A total of 90 studies were included: 35 prespecified end point analyses and 55 reanalyses. Circulatory system trials accounted for about 80% of the applications. We included 57 studies for comparison, and discrepancies between component-level results and overall conclusions were common. In prespecified end point analyses, 36 of 139 components (25.9%) had directional discordance or neutrality with the overall WR point estimate, compared with 17.0% in reanalyses, although the difference was not statistically significant (generalized linear mixed-effects model with study as a random effect, P = .114). Among the 35 studies included for conclusion-level comparison, 22 reached WR-reported conclusions that were consistent with those of the original trials. Nearly all observed discrepancies in conclusions were associated with changes in the selection or prioritization of end point components. CONCLUSION: The use of the WR in clinical research has steadily increased and is expanding beyond cardiovascular trials. Hierarchical composite end points constructed using the WR may differ from conventional composites in component selection, and directional discordance among components is not uncommon. In WR-reported reanalyses, changes to end point components may influence clinical interpretation. Careful attention to the appropriate use of the analytical framework, end point definition, and result interpretation is essential to ensure the interpretability and validity of WR-reported analyses.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Li Q, Zhu Y, Zhao Y, et al. The win ratio in contemporary clinical trials: growing adoption and interpretation challenges-a meta-epidemiological study. J Clin Epidemiol. 2026. PMID: 42128244. doi:10.1016/j.jclinepi.2026.112315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。